Myriad Genetics: Patent Law and Genetic Testing
Abstract
This paper considers the legal challenges to the legal validity of the patents held by Myriad Genetics in respect of genetic testing for breast cancer and ovarian cancer. It argues that broad-based patents on gene sequences and medical diagnostics will have a harmful effect upon access to patient care, genetic research, and the administration of public health care.
Suggested Citation
Matthew Rimmer. "Myriad Genetics: Patent Law and Genetic Testing" European Intellectual Property Review Jan. 2003: 20-33.
The full text of this version of the article is not currently available here.
Bookmark